{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:56:23Z","timestamp":1785189383167,"version":"3.55.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2009,3,21]],"date-time":"2009-03-21T00:00:00Z","timestamp":1237593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s00277-009-0736-4","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T23:55:56Z","timestamp":1237506956000},"page":"1047-1058","source":"Crossref","is-referenced-by-count":22,"title":["Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system"],"prefix":"10.1007","volume":"88","author":[{"given":"Susan","family":"L\u00f6sler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schlief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Kneifel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckhard","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Schrezenmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus T.","family":"Rojewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,3,21]]},"reference":[{"key":"736_CR1","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1080\/10428190412331272686","volume":"45","author":"MT Rojewski","year":"2004","unstructured":"Rojewski MT, Korper S, Schrezenmeier H (2004) Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. Leuk Lymphoma 45:2387\u20132401. doi: 10.1080\/10428190412331272686","journal-title":"Leuk Lymphoma"},{"key":"736_CR2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1185\/030079904X20349","volume":"21","author":"S Amadori","year":"2005","unstructured":"Amadori S, Fenaux P, Ludwig H, O\u2019Dwyer M, Sanz M (2005) Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin 21:403\u2013411. doi: 10.1185\/030079904X20349","journal-title":"Curr Med Res Opin"},{"key":"736_CR3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2174\/138920106779116829","volume":"7","author":"A Bonati","year":"2006","unstructured":"Bonati A, Rizzoli V, Lunghi P (2006) Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr Pharm Biotechnol 7:397\u2013405. doi: 10.2174\/138920106779116829","journal-title":"Curr Pharm Biotechnol"},{"key":"736_CR4","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1200\/JCO.2005.10.217","volume":"23","author":"D Douer","year":"2005","unstructured":"Douer D, Tallman MS (2005) Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23:2396\u20132410. doi: 10.1200\/JCO.2005.10.217","journal-title":"J Clin Oncol"},{"key":"736_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000092341","volume":"116","author":"SR Kalmadi","year":"2006","unstructured":"Kalmadi SR, Hussein MA (2006) The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. Acta Haematol 116:1\u20137. doi: 10.1159\/000092341","journal-title":"Acta Haematol"},{"key":"736_CR6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/emboj\/17.1.61","volume":"17","author":"S Muller","year":"1998","unstructured":"Muller S, Matunis MJ, Dejean A (1998) Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 17:61\u201370. doi: 10.1093\/emboj\/17.1.61","journal-title":"EMBO J"},{"key":"736_CR7","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1182\/blood.V92.11.4308","volume":"92","author":"S Muller","year":"1998","unstructured":"Muller S, Miller WH Jr, Dejean A (1998) Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. Blood 92:4308\u20134316","journal-title":"Blood"},{"key":"736_CR8","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1128\/MCB.19.7.5170","volume":"19","author":"T Sternsdorf","year":"1999","unstructured":"Sternsdorf T, Puccetti E, Jensen K et al (1999) PIC-1\/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol 19:5170\u20135178","journal-title":"Mol Cell Biol"},{"key":"736_CR9","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1084\/jem.193.12.1361","volume":"193","author":"V Lallemand-Breitenbach","year":"2001","unstructured":"Lallemand-Breitenbach V, Zhu J, Puvion F et al (2001) Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11\u00a0S proteasome recruitment, and As2O3-induced PML or PML\/retinoic acid receptor alpha degradation. J Exp Med 193:1361\u20131371. doi: 10.1084\/jem.193.12.1361","journal-title":"J Exp Med"},{"key":"736_CR10","first-page":"3345","volume":"89","author":"GQ Chen","year":"1997","unstructured":"Chen GQ, Shi XG, Tang W et al (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89:3345\u20133353","journal-title":"Blood"},{"key":"736_CR11","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1634\/theoncologist.5-6-454","volume":"5","author":"O Bruserud","year":"2000","unstructured":"Bruserud O, Gjertsen BT, Huang T (2000) Induction of differentiation and apoptosis\u2014a possible strategy in the treatment of adult acute myelogenous leukemia. Oncologist 5:454\u2013462. doi: 10.1634\/theoncologist.5-6-454","journal-title":"Oncologist"},{"key":"736_CR12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11912-000-0105-x","volume":"2","author":"EM Calleja","year":"2000","unstructured":"Calleja EM, Warrell RP (2000) Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia. Curr Oncol Rep 2:519\u2013523. doi: 10.1007\/s11912-000-0105-x","journal-title":"Curr Oncol Rep"},{"key":"736_CR13","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/jnci\/91.19.1690","volume":"91","author":"J Huff","year":"1999","unstructured":"Huff J, Waalkes M, Nyska A, Chan P (1999) Re: apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 91:1690\u20131691. doi: 10.1093\/jnci\/91.19.1690 letter","journal-title":"J Natl Cancer Inst"},{"key":"736_CR14","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/jnci\/91.9.772","volume":"91","author":"XH Zhu","year":"1999","unstructured":"Zhu XH, Shen YL, Jing YK et al (1999) Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 91:772\u2013778. doi: 10.1093\/jnci\/91.9.772","journal-title":"J Natl Cancer Inst"},{"key":"736_CR15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/tx034104+","volume":"17","author":"MT Rojewski","year":"2004","unstructured":"Rojewski MT, K\u00f6rper S, Thiel E, Schrezenmeier H (2004) Depolarization of mitochondria and activation of caspases are common features of arsenic(III)-induced apoptosis in myelogenic and lymphatic cell lines. Chem Res Toxicol 17:119\u2013128. doi: 10.1021\/tx034104+","journal-title":"Chem Res Toxicol"},{"key":"736_CR16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.febslet.2004.10.075","volume":"578","author":"F Nolte","year":"2004","unstructured":"Nolte F, Friedrich O, Rojewski M, Fink RH, Schrezenmeier H, Korper S (2004) Depolarisation of the plasma membrane in the arsenic trioxide (As2O3)-and anti-CD95-induced apoptosis in myeloid cells. FEBS Lett 578:85\u201389. doi: 10.1016\/j.febslet.2004.10.075","journal-title":"FEBS Lett"},{"key":"736_CR17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1046\/j.1365-2141.2003.04742.x","volume":"124","author":"S Korper","year":"2004","unstructured":"Korper S, Nolte F, Thiel E, Schrezenmeier H, Rojewski MT (2004) The role of mitochondrial targeting in arsenic trioxide-induced apoptosis in myeloid cell lines. Br J Haematol 124:186\u2013189. doi: 10.1046\/j.1365-2141.2003.04742.x","journal-title":"Br J Haematol"},{"key":"736_CR18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0378-4274(01)00373-3","volume":"123","author":"S Tsai","year":"2001","unstructured":"Tsai S, Hsieh M, Chen L, Liang Y, Lin J, Lin S (2001) Suppression of Fas ligand expression on endothelial cells by arsenite through reactive oxygen species. Toxicol Lett 123:11\u201319. doi: 10.1016\/S0378-4274(01) 00373-3","journal-title":"Toxicol Lett"},{"key":"736_CR19","first-page":"603","volume":"115","author":"J Yi","year":"2002","unstructured":"Yi J, Gao F, Shi G, Li H, Shi X, Tang X (2002) Apoptosis susceptibility of tumor cells to arsenic trioxide and the inherent cellular level of reactive oxygen species. Chin Med J (Engl) 115:603\u2013606","journal-title":"Chin Med J (Engl)"},{"key":"736_CR20","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0024-3205(01)01545-4","volume":"70","author":"Y Nakagawa","year":"2002","unstructured":"Nakagawa Y, Akao Y, Morikawa H et al (2002) Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 70:2253\u20132269. doi: 10.1016\/S0024-3205(01) 01545-4","journal-title":"Life Sci"},{"key":"736_CR21","first-page":"603","volume":"21","author":"YJ Choi","year":"2002","unstructured":"Choi YJ, Park JW, Suh SI et al (2002) Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt. Int J Oncol 21:603\u2013610","journal-title":"Int J Oncol"},{"key":"736_CR22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1046\/j.0007-1048.2001.03298.x","volume":"116","author":"MT Rojewski","year":"2002","unstructured":"Rojewski MT, Baldus C, Knauf W, Thiel E, Schrezenmeier H (2002) Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. Br J Haematol 116:555\u2013563. doi: 10.1046\/j.0007-1048.2001.03298.x","journal-title":"Br J Haematol"},{"key":"736_CR23","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1073\/pnas.88.11.4656","volume":"88","author":"J Martensson","year":"1991","unstructured":"Martensson J, Meister A (1991) Glutathione deficiency decreases tissue ascorbate levels in newborn rats: ascorbate spares glutathione and protects. Proc Natl Acad Sci USA 88:4656\u20134660. doi: 10.1073\/pnas.88.11.4656","journal-title":"Proc Natl Acad Sci USA"},{"key":"736_CR24","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1124\/mol.104.002048","volume":"66","author":"D Wu","year":"2004","unstructured":"Wu D, Cederbaum A (2004) Glutathione depletion in CYP2E1-expressing liver cells induces toxicity due to the activation of p38 mitogen-activated protein kinase and reduction of nuclear factor-kappaB DNA binding activity. Mol Pharmacol 66:749\u2013760. doi: 10.1124\/mol.104.002048","journal-title":"Mol Pharmacol"},{"key":"736_CR25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E","volume":"25","author":"A Macho","year":"1996","unstructured":"Macho A, Decaudin D, Castedo M et al (1996) Chloromethyl-X-Rosamine is an aldehyde-fixable potential-sensitive fluorochrome for the detection of early apoptosis. Cytometry 25:333\u2013340. doi: 10.1002\/(SICI) 1097-0320(19961201) 25:4<333::AID-CYTO4>3.0.CO;2-E","journal-title":"Cytometry"},{"key":"736_CR26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/(SICI)1097-0320(19990801)36:4<355::AID-CYTO11>3.0.CO;2-9","volume":"36","author":"K Gilmore","year":"1999","unstructured":"Gilmore K, Wilson M (1999) The use of chloromethyl-X-rosamine (Mitotracker red) to measure loss of mitochondrial membrane potential in apoptotic cells is incompatible with cell fixation. Cytometry 36:355\u2013358. doi: 10.1002\/(SICI) 1097-0320(19990801) 36:4<355::AID-CYTO11>3.0.CO;2-9","journal-title":"Cytometry"},{"key":"736_CR27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0887-2333(01)00013-3","volume":"15","author":"F Leira","year":"2001","unstructured":"Leira F, Vieites JM, Vieytes MR, Botana LM (2001) Apoptotic events induced by the phosphatase inhibitor okadaic acid in normal human lung fibroblasts. Toxicol In Vitro 15:199\u2013208. doi: 10.1016\/S0887-2333(01) 00013-3","journal-title":"Toxicol In Vitro"},{"key":"736_CR28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0165-0270(00)00340-X","volume":"104","author":"JF Buckman","year":"2001","unstructured":"Buckman JF, Hernandez H, Kress GJ, Votyakova TV, Pal S, Reynolds IJ (2001) MitoTracker labeling in primary neuronal and astrocytic cultures: influence of mitochondrial membrane potential and oxidants. J Neurosci Methods 104:165\u2013176. doi: 10.1016\/S0165-0270(00) 00340-X","journal-title":"J Neurosci Methods"},{"key":"736_CR29","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJM199811053391901","volume":"339","author":"SL Soignet","year":"1998","unstructured":"Soignet SL, Maslak P, Wang ZG et al (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341\u20131348. doi: 10.1056\/NEJM199811053391901","journal-title":"N Engl J Med"},{"key":"736_CR30","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","volume":"89","author":"ZX Shen","year":"1997","unstructured":"Shen ZX, Chen GQ, Ni JH et al (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354\u20133360","journal-title":"Blood"},{"key":"736_CR31","first-page":"83","volume":"7","author":"R Kapoor","year":"1995","unstructured":"Kapoor R, Slade DL, Fujimori A, Pommier Y, Harker WG (1995) Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol Res 7:83\u201395","journal-title":"Oncol Res"},{"key":"736_CR32","first-page":"1339","volume":"55","author":"A Fujimori","year":"1995","unstructured":"Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y (1995) Mutation at the catalytic site of topoisomerase I in CEM\/C2, a human leukemia cell line resistant to camptothecin. Cancer Res 55:1339\u20131346","journal-title":"Cancer Res"},{"key":"736_CR33","first-page":"58","volume":"17","author":"P Zhang","year":"1996","unstructured":"Zhang P, Wang SY, Hu XH (1996) Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 17:58\u201362","journal-title":"Chin J Hematol"},{"key":"736_CR34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ajh.10138","volume":"70","author":"V Mathews","year":"2002","unstructured":"Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A (2002) Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol 70:292\u2013299. doi: 10.1002\/ajh.10138","journal-title":"Am J Hematol"},{"key":"736_CR35","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1182\/blood.V94.10.3315.422k16_3315_3324","volume":"94","author":"C Niu","year":"1999","unstructured":"Niu C, Yan H, Yu T et al (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94:3315\u20133324","journal-title":"Blood"},{"key":"736_CR36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1445-5994.1999.tb00731.x","volume":"29","author":"A Spencer","year":"1999","unstructured":"Spencer A, Firkin F (1999) Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: initial Australian experience. Aust N Z J Med 29:385\u2013386 letter","journal-title":"Aust N Z J Med"},{"issue":"Suppl.","key":"736_CR37","first-page":"19","volume":"17","author":"RP Warrell Jr","year":"1998","unstructured":"Warrell RP Jr, Soignet SL, Maslak P et al (1998) Initial Western study of arsenic trioxide in acute promyelocytic leukemia. J Clin Oncol 17(Suppl.):19","journal-title":"J Clin Oncol"},{"key":"736_CR38","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/sj.leu.2402426","volume":"16","author":"K Ohnishi","year":"2002","unstructured":"Ohnishi K, Yoshida H, Shigeno K et al (2002) Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 16:617\u2013622. doi: 10.1038\/sj.leu.2402426","journal-title":"Leukemia"},{"key":"736_CR39","first-page":"248","volume":"70","author":"J Hu","year":"1999","unstructured":"Hu J, Shen ZX, Sun GL, Chen SJ, Wang ZY, Chen Z (1999) Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. Int J Hematol 70:248\u2013260","journal-title":"Int J Hematol"},{"key":"736_CR40","first-page":"107","volume":"113","author":"J Hu","year":"2000","unstructured":"Hu J, Shen Z, Sun H et al (2000) Long-term survey of outcome in acute promyelocytic leukemia. Chin Med J (Engl) 113:107\u2013110. doi: 10.3901\/JME.2000.08.107","journal-title":"Chin Med J (Engl)"},{"key":"736_CR41","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","volume":"19","author":"SL Soignet","year":"2001","unstructured":"Soignet SL, Frankel SR, Douer D et al (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852\u20133860","journal-title":"J Clin Oncol"},{"key":"736_CR42","first-page":"1107","volume":"111","author":"J Ni","year":"1998","unstructured":"Ni J, Chen G, Shen Z et al (1998) Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia. Chin Med J (Engl) 111:1107\u20131110","journal-title":"Chin Med J (Engl)"},{"key":"736_CR43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.6-suppl_2-11","volume":"6","author":"SL Soignet","year":"2001","unstructured":"Soignet SL (2001) Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist 6:11\u201316. doi: 10.1634\/theoncologist.6-suppl_2-11","journal-title":"Oncologist"},{"key":"736_CR44","first-page":"107","volume":"113","author":"H Jiong","year":"2000","unstructured":"Jiong H, Zhixiang S, Wen W, Xiusong L, Guanlin S, Zhenyi W (2000) Long-term survey of outcome in acute promyelocytic leukemia. Chin Med J (Engl) 113:107\u2013110","journal-title":"Chin Med J (Engl)"},{"key":"736_CR45","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.2000.18.13.2620","volume":"18","author":"LH Camacho","year":"2000","unstructured":"Camacho LH, Soignet SL, Chanel S et al (2000) Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 18:2620\u20132625","journal-title":"J Clin Oncol"},{"key":"736_CR46","first-page":"S257","volume":"4","author":"MA Hussein","year":"2003","unstructured":"Hussein MA, Elson P, Reed J et al (2003) Arsenic trioxide (Trisenox\u2122), ascorbic acid (AA), and dexamethasone (Dex) pulses-TAD for relapsed refractory progressive multiple myeloma patients. Hematol J 4:S257","journal-title":"Hematol J"},{"key":"736_CR47","first-page":"3658","volume":"8","author":"NJ Bahlis","year":"2002","unstructured":"Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I et al (2002) Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed\/refractory multiple myeloma. Clin Cancer Res 8:3658\u20133668","journal-title":"Clin Cancer Res"},{"key":"736_CR48","first-page":"123a","volume":"94","author":"NC Munshi","year":"1999","unstructured":"Munshi NC, Desikan R, Zangari M (1999) Marked anti-tumor effect of arsenic trioxide (As2O3) in high risk refractory multiple myeloma. Blood 94:123a","journal-title":"Blood"},{"key":"736_CR49","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/BF03165281","volume":"76","author":"NC Munshi","year":"2002","unstructured":"Munshi NC, Hideshima T, Chauhan D, Richardson P, Anderson KC (2002) Novel biologically based therapies for multiple myeloma. Int J Hematol 76:340\u2013341","journal-title":"Int J Hematol"},{"key":"736_CR50","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/sj.leu.2402599","volume":"16","author":"NC Munshi","year":"2002","unstructured":"Munshi NC, Tricot G, Desikan R et al (2002) Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 16:1835\u20131837. doi: 10.1038\/sj.leu.2402599","journal-title":"Leukemia"},{"key":"736_CR51","first-page":"1002","volume":"85","author":"A Donelli","year":"2000","unstructured":"Donelli A, Chiodino C, Panissidi T, Roncaglia R, Torelli G (2000) Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes? Haematologica 85:1002\u20131003","journal-title":"Haematologica"},{"key":"736_CR52","first-page":"560","volume":"27","author":"BD Cheson","year":"2000","unstructured":"Cheson BD, Zwiebel JA, Dancey J, Murgo A (2000) Novel therapeutic agents for the treatment of myelodysplastic syndromes. Semin Oncol 27:560\u2013577","journal-title":"Semin Oncol"},{"key":"736_CR53","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/sj.leu.2403021","volume":"17","author":"A List","year":"2003","unstructured":"List A, Beran M, DiPersio J et al (2003) Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 17:1499\u20131507. doi: 10.1038\/sj.leu.2403021","journal-title":"Leukemia"},{"key":"736_CR54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1023\/A:1016270206374","volume":"20","author":"J Vuky","year":"2002","unstructured":"Vuky J, Yu R, Schwartz L, Motzer RJ (2002) Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs 20:327\u2013330. doi: 10.1023\/A:1016270206374","journal-title":"Invest New Drugs"},{"key":"736_CR55","first-page":"1071","volume":"20","author":"V Lecureur","year":"2002","unstructured":"Lecureur V, Lagadic-Gossmann D, Fardel O (2002) Potassium antimonyl tartrate induces reactive oxygen species-related apoptosis in human myeloid leukemic HL60 cells. Int J Oncol 20:1071\u20131076","journal-title":"Int J Oncol"},{"key":"736_CR56","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.toxlet.2005.06.017","volume":"160","author":"KK Mann","year":"2006","unstructured":"Mann KK, Davison K, Colombo M et al (2006) Antimony trioxide-induced apoptosis is dependent on SEK1\/JNK signaling. Toxicol Lett 160:158\u2013170. doi: 10.1016\/j.toxlet.2005.06.017","journal-title":"Toxicol Lett"},{"key":"736_CR57","first-page":"566","volume":"8","author":"RB Gartenhaus","year":"2002","unstructured":"Gartenhaus RB, Prachand SN, Paniaqua M, Li Y, Gordon LI (2002) Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 8:566\u2013572","journal-title":"Clin Cancer Res"},{"key":"736_CR58","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1021\/tx000123x","volume":"14","author":"S Chouchane","year":"2001","unstructured":"Chouchane S, Snow ET (2001) In vitro effect of arsenical compounds on glutathione-related enzymes. Chem Res Toxicol 14:517\u2013522. doi: 10.1021\/tx000123x","journal-title":"Chem Res Toxicol"},{"key":"736_CR59","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1006\/excr.1999.4519","volume":"249","author":"N Larochette","year":"1999","unstructured":"Larochette N, Decaudin D, Jacotot E et al (1999) Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 249:413\u2013421. doi: 10.1006\/excr.1999.4519","journal-title":"Exp Cell Res"},{"key":"736_CR60","doi-asserted-by":"crossref","first-page":"13704","DOI":"10.1016\/S0021-9258(18)33504-X","volume":"257","author":"OW Griffith","year":"1982","unstructured":"Griffith OW (1982) Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 257:13704\u201313712","journal-title":"J Biol Chem"},{"key":"736_CR61","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood.V93.1.268","volume":"93","author":"J Dai","year":"1999","unstructured":"Dai J, Weinberg RS, Waxman S, Jing Y (1999) Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93:268\u2013277","journal-title":"Blood"},{"key":"736_CR62","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood.V94.6.2102","volume":"94","author":"Y Jing","year":"1999","unstructured":"Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94:2102\u20132111","journal-title":"Blood"},{"key":"736_CR63","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s002440010223","volume":"41","author":"S Chattopadhyay","year":"2001","unstructured":"Chattopadhyay S, Ghosh S, Debnath J, Ghosh D (2001) Protection of sodium arsenite-induced ovarian toxicity by coadministration of l-ascorbate (vitamin C) in mature Wistar strain rat. Arch Environ Contam Toxicol 41:83\u201389. doi: 10.1007\/s002440010223","journal-title":"Arch Environ Contam Toxicol"},{"key":"736_CR64","doi-asserted-by":"crossref","first-page":"909","DOI":"10.7326\/0003-4819-114-10-909","volume":"114","author":"G Block","year":"1991","unstructured":"Block G, Henson DE, Levine M (1991) Vitamin C: a new look. Ann Intern Med 114:909\u2013910","journal-title":"Ann Intern Med"},{"key":"736_CR65","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/(SICI)1098-2280(1997)30:3<339::AID-EM13>3.0.CO;2-E","volume":"30","author":"GN Bijur","year":"1997","unstructured":"Bijur GN, Ariza ME, Hitchcock CL, Williams MV (1997) Antimutagenic and promutagenic activity of ascorbic acid during oxidative stress. Environ Mol Mutagen 30:339\u2013345. doi: 10.1002\/(SICI) 1098-2280(1997) 30:3<339::AID-EM13>3.0.CO;2-E","journal-title":"Environ Mol Mutagen"},{"key":"736_CR66","first-page":"3513","volume":"17","author":"H Sakagami","year":"1997","unstructured":"Sakagami H, Satoh K (1997) Modulating factors of radical intensity and cytotoxic activity of ascorbate. Anticancer Res 17:3513\u20133520 Review","journal-title":"Anticancer Res"},{"key":"736_CR67","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/02841860601042456","volume":"46","author":"PR Subbarayan","year":"2007","unstructured":"Subbarayan PR, Lima M, Ardalan B (2007) Arsenic trioxide\/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta Oncol 46:557\u2013561. doi: 10.1080\/02841860601042456","journal-title":"Acta Oncol"},{"key":"736_CR68","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1158\/1078-0432.CCR-06-1812","volume":"13","author":"JR Berenson","year":"2007","unstructured":"Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Yeh HS (2007) A phase I\/II study of arsenic trioxide\/bortezomib\/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 13:1762\u20131768. doi: 10.1158\/1078-0432.CCR-06-1812","journal-title":"Clin Cancer Res"},{"key":"736_CR69","first-page":"1722","volume":"91","author":"KL Wu","year":"2006","unstructured":"Wu KL, Beksac M, van Droogenbroeck J, Amadori S, Zweegman S, Sonneveld P (2006) Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica 91:1722\u20131723","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-009-0736-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-009-0736-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-009-0736-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T12:31:55Z","timestamp":1633264315000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-009-0736-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,21]]},"references-count":69,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["736"],"URL":"https:\/\/doi.org\/10.1007\/s00277-009-0736-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,21]]}}}